RosVivo Therapeutics
RosVivo Therapeutics is dedicated to reversing diseases such as Type 2 Diabetes, obesity, fatty liver disease, hyperlipidemia, and gastroparesis through breakthrough therapies utilizing microRNA (miRNA) and small interfering-RNA (siRNA) drugs. Their mission is to target metabolic diseases with innovative treatments based on key miRNAs responsible for disease onset and development, with the aim of reversing these disease states.
Industries
Nr. of Employees
small (1-50)
RosVivo Therapeutics
Products
miRNA-based therapeutic candidates for metabolic and gastrointestinal diseases
Lead therapeutic oligonucleotide candidates developed to modulate microRNA pathways with the aim of reversing type 2 diabetes, obesity, NAFLD, and gastrointestinal dysmotility; efficacy shown in preclinical in vitro and in vivo models and supported by peer-reviewed publications.
miRNA-based therapeutic candidates for metabolic and gastrointestinal diseases
Lead therapeutic oligonucleotide candidates developed to modulate microRNA pathways with the aim of reversing type 2 diabetes, obesity, NAFLD, and gastrointestinal dysmotility; efficacy shown in preclinical in vitro and in vivo models and supported by peer-reviewed publications.
Services
Collaborative preclinical research services focused on discovery, target validation, and efficacy testing of small RNA therapeutic candidates in metabolic and gastrointestinal disease models.
Collaborative preclinical research services focused on discovery, target validation, and efficacy testing of small RNA therapeutic candidates in metabolic and gastrointestinal disease models.
Expertise Areas
- microRNA and siRNA therapeutics development
- Preclinical metabolic disease models (diabetes, obesity, NAFLD)
- Gastrointestinal motility research and translational studies
- Target identification and validation for RNA-based drugs
Key Technologies
- microRNA (miRNA) therapeutics
- small interfering RNA (siRNA)
- In vitro cellular assays
- In vivo animal models (rodent diabetic and GI motility models)
News & Updates
In 2022, Dr. Seungil Ro secured funding for preclinical studies of therapeutic microRNAs aimed at treating diabetes.
University of Nevada, Reno School of Medicine researcher Dr. Seungil Ro was awarded $2 million for research on a molecule that could be key to curing type 2 diabetes.
In 2022, Dr. Seungil Ro secured funding for preclinical studies of therapeutic microRNAs aimed at treating diabetes.
University of Nevada, Reno School of Medicine researcher Dr. Seungil Ro was awarded $2 million for research on a molecule that could be key to curing type 2 diabetes.